Danish Immunology Society

Annual Meeting

23rd August 2021
J.B. Winsløws Vej 25

KEYNOTE SPEAKERS:

DOMINIK PFISTER
Senior Reseach Scientist, Novo Nordisk

KEN COPPIETERS
Research Project Vice president, Novo Nordisk

Organizing committee:
Jesper Bonnet Møller and Mikkel Green Terp

Sponsors 2021:

We thank our sponsors

PROGRAM

10.00-10.30	Registration, Sponsor Exhibitions, Setting up posters and coffee.
10.30	Welcome and practical information by the chairman, Rune Hartmann
10.30-11.15	KEYNOTE LECTURE: NASH disrupts and limits anti-tumour surveillance in immunotherapy-treated liver cancer Dominik Pfister, Senior Reseach Scientist, Novo Nordisk
SESSION I Chair:	Torben Barington, Professor, MD, Department of Clinical Immunology, OUH
11.15-11.30	Development of BAFF-R-specific chimeric antigen receptor T cells. Mike B. Barnkob (Abstract #21)
11.30-11.45	Combination of radio- and immunocytokine L19-IL2 therapy alters immune compartment in both human and mice. Mohammad Kadivar (Abstract #17)
11.45-12.00	Targeting human CD73 by a bispecific antibody exhibits potent anti-cancer effect towards triple-negative breast cancer Odd L. Gammelgaard (Abstract #7)
12.00-12.15	Aiming high in HI-AIM; A clinical testing of exercise in cancer Gitte Holmen Olofsson: (Abstract #16)
12.15-13.15	Lunch/Posters/Exhibition (General Assembly of DIS 12.45-13.15)
13.15-14.00	KEYNOTE LECTURE: Anti-interleukin-21 therapy from bench to bedside Ken Coppieters, Research Project Vice president, Novo Nordisk
SESSION II: Chair:	Lars Hviid, Professor, University of Copenhagen
14.00-14.15	Pathways for protection in cortical brain lesions Bhavya Ojha (Abstract #13)
14.15-14.30	Antibody-mediated blocking of Microfibrillar-associated protein 4 (MFAP4) inhibits carbon tetrachloride-induced liver fibrosis in rats Reine Kanaan (Abstract #23)
14.30-14.45	Effector functions induced by malaria-specific IgG are associated with Fc glycosylation patters Mary Lopez-Perez (Abstract #19)
14:45	Two cGAS-like receptors induce antiviral immunity in *Drosophila melanogaster* Hans H. Gad (Abstract #26)
15:00:16:00	Coffee/Posters/Sponsor Exhibition

Session III:
Chair: Grith Lykke Sørensen, Professor, University of Southern Denmark

16.00-16.15 **Investigating the extrafollicular and germinal center responses in SLE**
Lasse F. Voss (Abstract #1)

16.15-16.30 **Mesenchymal stromal cells within human gut-associated lymphoid tissues establish specialized microniches for intestinal lymphocytes**
Urs M. Mörbe (Abstract #11)

16.30-16.45 **Studying viral disease pathogenesis in mouse models carrying patient specific immune gene variants**
Manja Idorn (Abstract #6)

16.45-17.00 **Cellular inhibitor of apoptosis proteins act as negative regulators on Th17 during psoriasis like skin inflammation**
Rasmus Agerholm-Nielsen (Abstract #22)

17.00-18.00 Refreshments/Exhibition/Posters

18:00 - Reception/Dinner

Dominik Pfister, Senior Reseach Scientist, Novo Nordisk

Dominik Pfister studied Biochemistry in Ulm, Germany, pursued a Ph.D. and a post-doc in the group of Prof. Mathias Heikenwaelder at the German Cancer Research Institute (DKFZ) in Heidelberg, Germany. There he focused on chronic necro-inflammation by dissecting the role of T cells in non-alcoholic fatty liver disease (NAFLD), its more severe form non-alcoholic steatohepatitis (NASH), subsequent liver cancer development, and how the hepatic NASH-environment limits anti-tumour surveillance of liver cancer upon PD1-targeted immunotherapy. Key findings were published in two Nature papers in March 2021.
He joined Novo Nordisk to target and disrupt the cycle of chronic metabolic-associated inflammation.

Ken Coppieters, Research Project Vice president, Novo Nordisk

Master in Biotechnology, PhD in Medicine (rheumatology) both at Ghent University, Belgium. Postdoc in diabetes immunology at La Jolla Institute, USA. Been at Novo Nordisk for nine years, went from scientist on type 1 diabetes projects to currently project vice president. Leading two siRNA drug projects toward first-in-human trials for NASH and one heart failure project toward lead candidate selection.